Skip to content

Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults

Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02552875
Acronym
STSTS
Enrollment
80
Registered
2015-09-17
Start date
2014-09-30
Completion date
2015-09-30
Last updated
2015-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Train-of-Four-Monitoring

Keywords

Acceleromyography, staircase phenomenon, tetanic stimulation

Brief summary

Repetitive nerve stimulation is used to monitor the neuromuscular transmission function in infants, children and adults after the application of muscle relaxants. During repetitive stimulation of a motor nerve, amplitude of contractions of the corresponding muscle will increase to a plateau (twitch potentiation), which is known as the staircase phenomenon. There is no systematic information about the staircase phenomenon of the adductor pollices muscle (ulnar nerve) in children between 1 month and 18 years . In adults , a 50-Hz tetanus administered before initial twitch stabilization is able to shorten the twitch stabilization period and to eliminate this staircase phenomenon. The purpose of this study is to investigate the characteristics of twitch potentiation in children between 1 month and 18 years by using acceleromyography. In addition we investigate whether application of a 50-Hz tetanic stimulation is able to eliminate the twitch potentiation like in adults.

Detailed description

1. Background: Acceleromyography at the adductor pollices muscle (ulnar nerve stimulation) is used to monitor the neuromuscular transmission function in infants, children and adults after the application of muscle relaxants. During repetitive stimulation of a motor nerve, amplitude of contractions of the corresponding muscle will increase to a plateau (twitch potentiation), which is known as the staircase phenomenon. This effect may influence the onset time and duration of twitch depression after the application of muscle relaxants. The staircase effect during the baseline stabilization period presents in a shorter time course and at lower degrees in smaller infants. In older infants, staircase effect presents in a longer period and is able to influence duration of twitch depression after the administration of muscle relaxants. There is no information about the staircase phenomenon at the adductor pollices muscle (ulnar nerve stimulation) in children between 1 month and 21 years. In adults , a 50-Hz tetanus administered before initial twitch stabilization is able to shorten the twitch stabilization period and to eliminate this phenomenon. 2. Aim of the study: The purpose of this controlled, randomised, pragmatic study is to investigate the characteristics of twitch potentiation (T1%, first twitch of TOF-stimulation; TOFR, Train-of-Four-ratio) in children between 1 month and 21 years by using acceleromyography. In addition we stimulate the right and the left arm simultaneously with acceleromyography (TOF-stimulation). At the one hand a 50 Hz tetanus will be administered before twitch stabilization (TOF-stimulation). At the other hand TOF-stimulation for twitch stabilization will be started without tetanic stimulation 3. Methods: Anaesthesia will be induced and maintained without muscle relaxants by propofol and remifentanil. After this acceleromyography will be performed simultaneously at the right and the left arm (adductor pollices muscle, ulnar nerve). At the one hand a 50 Hz tetanus will be administered before twitch stabilization (TOF-stimulation). At the contralateral side TOF-stimulation for twitch stabilization will be started without tetanus. TOF measurements will be collected by 2 TOF Watch SX and two notebooks for the course of 30 minutes. 4. Inclusion criterions/ groups -general anesthesia (total intravenous anaesthesia) Groups (total amount= 80) * group A: 18-21 years; n= 10 * group B: 12-18 years; n= 10 * group C: 6-12 years; n= 10 * group D: 3-6 years; n= 10 * group E: 25-60 months; n= 10 * group F: 12-24 months; n= 10 * group G: 6-11 months; n= 10 * group H: 1-5 months; n= 10. 5. Exclusion criterions * participation in another trial * refusal of participation * state after burns * diabetes mellitus * reflux disease * difficult airway * pregnancy Medications: * volatile anesthetics * antibiotics (aminoglycosides, polymyxin, clindamycin, lincomycin, tetracyclines) * local anesthetics * magnesium * lithium * Ca-chanel-blockers * furosemide * theophylline * phenytoin * cyclophosphamide * metoclopramide * β-blockers

Interventions

50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon

OTHERStaircase Stimulation

TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon

Sponsors

University of Regensburg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* general anesthesia

Exclusion criteria

* participation in another trial * refusal of participation * state after burns * diabetes mellitus * reflux disease * difficult airway * pregnancy Medications: * volatile anesthetics * antibiotics (Aminoglykoside, Polymyxin, Clindamycin, Lincomycin, Tetrazykline) * local anesthetics * magnesium * Litium * Ca-chanel-blockers * furosemid * theophyllin * phenytoin * cyclophosphamide * metoclopramide * β-blockers

Design outcomes

Primary

MeasureTime frameDescription
T1% measurement30 minutesT1% increase dependent on stimulation with and without a 50 Hz tetanic stimulation

Secondary

MeasureTime frameDescription
TOFR% maesurement30 minutesTOFR%course dependent on stimulation with and without a 50 Hz tetanic stimulation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026